ライフサイエンスコーパス: gastrointestinal bleeding

1 cularly among the elderly-a greater risk for gastrointestinal bleeding.

2 (NSAIDs), which further increase the risk of gastrointestinal bleeding.

3 ain, signs of acute pancreatitis and massive gastrointestinal bleeding.

4 ransfusion for all patients with acute upper gastrointestinal bleeding.

5 atal bleeding, intracranial haemorrhage, and gastrointestinal bleeding.

6 e the association between SSRI use and upper gastrointestinal bleeding.

7 ajor bleeding, intracranial haemorrhage, and gastrointestinal bleeding.

8 ajor bleeding as for warfarin, but increased gastrointestinal bleeding.

9 tonin transporter were associated with upper gastrointestinal bleeding.

10 the relationship between SSRI use and upper gastrointestinal bleeding.

11 tionally, TSOACs do not increase the risk of gastrointestinal bleeding.

12 days) is significantly associated with upper gastrointestinal bleeding.

13 D), a group with a high risk of both VTE and gastrointestinal bleeding.

14 lly relevant nonmajor bleeding, but not with gastrointestinal bleeding.

15 ed to elderly patients increases the risk of gastrointestinal bleeding.

16 clinically significant risk for NOAC-related gastrointestinal bleeding.

17 venting clinically important and overt upper gastrointestinal bleeding.

18 Timing of endoscopy for acute upper gastrointestinal bleeding.

19 in treating patients with non-variceal upper gastrointestinal bleeding.

20 reases the risks for portal hypertension and gastrointestinal bleeding.

21 as a composite of intracranial hemorrhage or gastrointestinal bleeding.

22 proved outcomes in patients with acute upper gastrointestinal bleeding.

23 ding (HR, 1.70 [95% CI, 1.16-2.48]), but not gastrointestinal bleeding.

24 PPIs are commonly used to prevent gastrointestinal bleeding.

25 reasingly recognized as important sources of gastrointestinal bleeding.

26 Is in selected high-risk patients to prevent gastrointestinal bleeding.

27 ize cardiac benefit and minimize the risk of gastrointestinal bleeding.

28 ia, vascular malformations that cause severe gastrointestinal bleeding.

29 actic use of a PPI reduced the rate of upper gastrointestinal bleeding.

30 s but are associated with increased risks of gastrointestinal bleeding.

31 se, small-bowel obstruction, and unexplained gastrointestinal bleeding.

32 ers that cause abdominal pain, diarrhea, and gastrointestinal bleeding.

33 All patients had complete relief from gastrointestinal bleeding.

34 peutic strategies in the management of lower gastrointestinal bleeding.

35 an important role in the management of lower gastrointestinal bleeding.

36 ces in the diagnosis and management of upper gastrointestinal bleeding.

37 d the majority (43 of 52) did so for obscure gastrointestinal bleeding.

38 d morbidity and death from radiation-induced gastrointestinal bleeding.

39 on major cardiovascular events but increased gastrointestinal bleeding.

40 irin, without a significantly higher risk of gastrointestinal bleeding.

41 ble tool for detecting the location of acute gastrointestinal bleeding.

42 sfusion policies for adults with acute upper gastrointestinal bleeding.

43 were found to be at increased risk for major gastrointestinal bleeding.

44 considered fundamental for the diagnosis of gastrointestinal bleeding.

45 l RBC transfusion strategies for acute upper gastrointestinal bleeding.

46 age without hypertension or risk factors for gastrointestinal bleeding.

47 substantial risk of disabling or fatal upper gastrointestinal bleeding.

48 tically ill patients for prophylaxis against gastrointestinal bleeding.

49 3%, $9,180), whereas sepsis (0.8%, $33,009), gastrointestinal bleeding (0.5%, $32,835), fistula (0.2%

50 risk of major bleeding (0.74; 0.60-0.91) and gastrointestinal bleeding (0.58; 0.41-0.82) versus dabig

51 r colorectal neoplasm (3 pts, 27%) and lower gastrointestinal bleeding (1 pts, 9%).

52 e (0.48, 0.39-0.59; p<0.0001), but increased gastrointestinal bleeding (1.25, 1.01-1.55; p=0.04).

53 od transfusion (10.4% versus 10.8%; P=0.70), gastrointestinal bleeding (1.4% versus 1.8%; P=0.35), or

54 acranial hemorrhage, 0.34 (0.26-0.46); major gastrointestinal bleeding, 1.28 (1.14-1.44); acute myoca

55 d 148 patients with severe nonvariceal upper gastrointestinal bleeding (125 with ulcers, 19 with Dieu

56 rmed for ascites (159 of 334 patients, 48%), gastrointestinal bleeding (127 of 334 patients, 38%), or

57 n (22 [2%] patients vs 33 [3%] patients) and gastrointestinal bleeding (13 [1%] vs ten [1%]).

58 opies were changes in bowel habits (18%) and gastrointestinal bleeding (17%).

59 The recurrence rates of gastrointestinal bleeding (18.3% vs. 33.9%, P = 0.004) a

60 alidated in 288 patients admitted with lower gastrointestinal bleeding (184 safely discharged) from t

61 leeding in 3 of 10 patients with symptoms of gastrointestinal bleeding (30%).

62 % vs. 40.8%, p = .004) and history of recent gastrointestinal bleeding (41% vs. 7%, p < .001) were mo

63 Gastrointestinal bleeding (61.7%) was the most frequent

64 ing pulmonary alveolar [11.8% and 15.6%] and gastrointestinal bleeding [7.8% and 9.4%]) was similar b

65 r bleeding (14%), driveline infection (10%), gastrointestinal bleeding (8%), and debilitating stroke

66 report reveals a very rare cause of obscure gastrointestinal bleeding accompanied by the episodes of

67 endoscopy was noted to be 68.1% for obscure gastrointestinal bleeding according to a systematic revi

68 ocardial myocardial infarction (secondary to gastrointestinal bleeding after an intentional overdose

69 The authors explored the risk of upper gastrointestinal bleeding after short-term SSRI exposure

70 he adjusted odds ratio for the risk of upper gastrointestinal bleeding after SSRI exposure was 1.67 (

71 An elevated risk of upper gastrointestinal bleeding after SSRI exposure was seen i

72 A PELD score of >/=15, history of gastrointestinal bleeding, age at FO initiation >/=16 wk

73 vitamin D3 and n = 26 receiving placebo) and gastrointestinal bleeding among 45 (n = 28 receiving ome

74 icle aims to evaluate the real world risk of gastrointestinal bleeding among users naive to dabigatra

75 mbolus, pneumothorax, myocardial infarction, gastrointestinal bleeding, anaphylaxis with a difficult

76 group A, 137 patients (45.5%) presented with gastrointestinal bleeding and 98 (32.6%) presented with

77 ned patients with overt signs of acute upper gastrointestinal bleeding and a Glasgow-Blatchford score

78 INTRODUCTION: A decreased frequency of upper gastrointestinal bleeding and a possible association of

79 nagement of patients with unclear sources of gastrointestinal bleeding and allows for effective hemor

80 /10ib mice, as well as significantly reduced gastrointestinal bleeding and anemia in inducible ALK1-d

81 and hepatic encephalopathy are common after gastrointestinal bleeding and can be simulated by an ami

82 ing severe enough to result in massive upper gastrointestinal bleeding and death.

83 Drug-induced gastrointestinal bleeding and drug-induced pancreatitis

84 ctopic pancreas in the ileum causing obscure gastrointestinal bleeding and episodes of abdominal pain

85 tral prosthesis dysfunction, with occasional gastrointestinal bleeding and gastrointestinal angiodysp

86 suspected pump thrombosis) and hemorrhagic (gastrointestinal bleeding and hemorrhagic stroke) events

87 (CVD) and low 10-year CVD risk, the risks of gastrointestinal bleeding and hemorrhagic strokes associ

88 Initially, he had abdominal pain, gastrointestinal bleeding and hypotension.

89 suspension is effective in preventing upper gastrointestinal bleeding and more effective than intrav

90 ection of this trend was consistent for both gastrointestinal bleeding and nongastrointestinal bleedi

91 ary outcomes were clinically important upper gastrointestinal bleeding and overt upper gastrointestin

92 nrolled 921 patients with severe acute upper gastrointestinal bleeding and randomly assigned 461 of t

93 nes in management of acute nonvariceal upper gastrointestinal bleeding and reviews recent advances in

94 The current rate of upper gastrointestinal bleeding and the relative adverse effec

95 the very near future the detection of upper gastrointestinal bleeding and to survey high-risk patien

96 t to recognize potential etiologies of upper gastrointestinal bleeding and understand therapeutic mod

97 monary hypertension, and one episode each of gastrointestinal bleeding and wound healing complication

98 onship between the treatment effect (risk of gastrointestinal bleeding) and the classification used t

99 idal antiinflammatory medications in 6-month gastrointestinal bleeding, and a study of simvastatin +

100 tients with Crohn's disease, celiac disease, gastrointestinal bleeding, and anemia.

101 illance, quality of inpatient care for upper gastrointestinal bleeding, and cirrhosis-related rehospi

102 .25%) had hemorrhagic stroke, 107 (6.8%) had gastrointestinal bleeding, and five (0.3%) required majo

103 of spontaneous bacterial peritonitis, upper gastrointestinal bleeding, and low-protein ascites with

104 e of SPECT/CT and CT angiography to evaluate gastrointestinal bleeding, and Meckel diverticulum imagi

105 In patients with overt gastrointestinal bleeding, and negative findings on esop

106 stinal hypomotility, constipation, diarrhea, gastrointestinal bleeding, and pancreatitis in criticall

107 stinal hypomotility, constipation, diarrhea, gastrointestinal bleeding, and pancreatitis, and should

108 ites, patients that received antibiotics for gastrointestinal bleeding, and patients that required di

109 cirrhosis, patients with non-variceal upper gastrointestinal bleeding, and patients with ischaemic h

110 disease, gastroesophageal reflux disease, or gastrointestinal bleeding, and prior use of histamine-2

111 ntially requiring intubation; 18.4%), severe gastrointestinal bleeding/anemia (15.7%), stroke (9.7%),

112 city during the run-in period, with no upper gastrointestinal bleeding (any grade) in the gastro-oeso

113 Infections in cirrhotic patients with upper gastrointestinal bleeding are a common event causing sev

114 Transfusion thresholds for acute upper gastrointestinal bleeding are controversial.

115 The reasons for gastrointestinal bleedings are manifold.

116 of major gastrointestinal bleeding, with all gastrointestinal bleeding as a secondary outcome.

117 ial to the management of patients with upper gastrointestinal bleeding as meticulous hemostatic techn

118 lar to HHT patients, the mice also exhibited gastrointestinal bleeding, as evidenced by positive feca

119 of portal hypertension, hepatosplenomegaly, gastrointestinal bleeding, ascites, thrombocytopenia, es

120 This review will quantify the risk of gastrointestinal bleeding associated with common cardiop

121 (10%) patient was admitted to hospital with gastrointestinal bleeding at month 1; one (10%) patient

122 There was no significant difference in major gastrointestinal bleeding between TSOACs and VKAs (RR 0.

123 te of readmission due to hemorrhagic stroke, gastrointestinal bleeding, bleeding causing anemia, and

124 Clinically significant upper gastrointestinal bleeding (bright red blood not clearing

125 e the risk of serious warfarin-related upper gastrointestinal bleeding, but the evidence of their eff

126 Localizing obscure gastrointestinal bleeding can be a clinical challenge, d

127 ary outcomes were clinically important upper gastrointestinal bleeding, Clostridioides difficile infe

128 atistically lower mortality in patients with gastrointestinal bleeding compared with liberal transfus

129 ted with a reduced risk of all severities of gastrointestinal bleeding compared with warfarin (0.25 [

130 myocardial infarction or hospitalization for gastrointestinal bleeding compared with warfarin.

131 inal bleeding, which often presents as lower gastrointestinal bleeding, continues to be one of the mo

132 idered a complementary test in patients with gastrointestinal bleeding, Crohn's disease, or celiac di

133 Upper gastrointestinal bleeding developed in 6.1% of patients

134 he small bowel include evaluation of obscure gastrointestinal bleeding, diagnosis and surveillance of

135 However, the 10-year risk of gastrointestinal bleeding did not differ significantly b

136 One-third of patients admitted with upper gastrointestinal bleeding died within 60 days of admissi

137 This case presents a seldom cause of a gastrointestinal bleeding due to an aneurysma of the hep

138 .1% overall and 12.0% among those with lower gastrointestinal bleeding during pediatric colonoscopy.

139 nagement of patients presenting with obscure gastrointestinal bleeding during the period from 2005 to

140 tate the analysis of inflammatory lesions or gastrointestinal bleeding during wireless capsule endosc

141 cohort of 202 patients with CC (no ascites, gastrointestinal bleeding, encephalopathy, or jaundice)

142 ents with compensated cirrhosis (no ascites, gastrointestinal bleeding, encephalopathy, or jaundice)

143 2012 with use of dabigatran and at least one gastrointestinal bleeding episode.

144 ians should carefully monitor signs of upper gastrointestinal bleeding even after short-term exposure

145 he risk for major bleeding events, primarily gastrointestinal bleeding events, in both men and women.

146 rmed a significantly increased risk of lower gastrointestinal bleeding following polypectomy in patie

147 from the National Comparative Audit of Lower Gastrointestinal Bleeding from 143 hospitals in the UK i

148 ancreatic necrosis, management of refractory gastrointestinal bleeding from gastric varix or vasculat

149 Upper gastrointestinal bleeding from peptic ulcer disease is n

150 Acute upper gastrointestinal bleedings from ulcers or esophago-gastr

151 are a fast emerging population vulnerable to gastrointestinal bleeding (GIB) due to their use of anti

152 The incidence of upper gastrointestinal bleeding (GIB) has not been reduced des

153 d the incidence, predictors, and outcomes of gastrointestinal bleeding (GIB) in patients with acute c

154 The risk factors and clinical sequelae of gastrointestinal bleeding (GIB) in the current era of dr

155 both the location and the severity of acute gastrointestinal bleeding (GIB) to optimize the diagnost

156 ther these drugs increase patients' risk for gastrointestinal bleeding (GIB).

157 thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international ra

158 luded clinically relevant nonmajor bleeding, gastrointestinal bleeding, heart failure hospitalization

159 sed, the incidence of clinically significant gastrointestinal bleeding, hospital-acquired pneumonia,

160 zations (HR, 1.07; 95% CI, 0.94-1.22) or non-gastrointestinal bleeding hospitalizations (HR, 0.98; 95

161 o significant reduction in the risk of other gastrointestinal bleeding hospitalizations (HR, 1.07; 95

162 , those without PPI co-therapy had 284 upper gastrointestinal bleeding hospitalizations per 10,000 pe

163 ed liver cirrhosis is commonly caused due to gastrointestinal bleeding; however, sometimes, detecting

164 More gastrointestinal bleeding (HR, 1.14 [CI, 1.06 to 1.22];

165 terectomy included systemic infection in 11, gastrointestinal bleeding in 1, and severe electrolyte i

166 uiring reversal (n = 59; 70.2%), followed by gastrointestinal bleeding in 13 (15.5%) patients.

167 ompare rates of clinically significant upper gastrointestinal bleeding in a prospective, phase 3, dou

168 IEW: Colorectal polyps are a common cause of gastrointestinal bleeding in children.

169 ptor antagonists for the prevention of upper gastrointestinal bleeding in critically ill patients, pu

170 tingly, a significant lengthy control of the gastrointestinal bleeding in one of our patients was ach

171 of stress ulcer prophylaxis to prevent upper gastrointestinal bleeding in patients with bleeding risk

172 tric and duodenal motility, risk factors for gastrointestinal bleeding in pediatric intensive care un

173 ular carcinoma, liver-related mortality, and gastrointestinal bleeding in persons with chronic hepati

174 re 13 physician-confirmed diagnoses of upper gastrointestinal bleeding in the polypill group and nine

175 ration of fresh frozen plasma (FFP) prevents gastrointestinal bleeding in this individual, its effect

176 ted of 16 patients with clinical symptoms of gastrointestinal bleeding in whom features of active ble

177 Gastrointestinal bleeding incidence and case-fatality ra

178 cusses key issues in the management of upper gastrointestinal bleeding including patient preparation,

179 significant difference in the risk of upper gastrointestinal bleeding, infections, or mortality.

180 Major outcomes were clinically significant gastrointestinal bleeding, infective ventilator-associat

181 Previous major bleeding events were major gastrointestinal bleeding, intracranial bleeding, sponta

182 older with new presentations of acute upper gastrointestinal bleeding, irrespective of comorbidity,

183 Acute lower gastrointestinal bleeding is a common reason for emergen

184 Acute upper gastrointestinal bleeding is a leading indication for re

185 Upper gastrointestinal bleeding is a serious complication, but

186 Acute gastrointestinal bleeding is an emergency with a high mo

187 RECENT FINDINGS: Gastrointestinal bleeding is associated with higher rate

188 ss of transfusion strategies for acute upper gastrointestinal bleeding is both feasible and essential

189 nsfusion of red cells in patients with acute gastrointestinal bleeding is controversial.

190 Gastrointestinal bleeding is now associated with lower m

191 Acute upper gastrointestinal bleeding is one of the most common medi

192 luation and Management of Occult and Obscure Gastrointestinal Bleeding." It was approved by the Clini

193 ause adverse side effects such as infection, gastrointestinal bleeding, kidney failure, and liver fib

194 rospective evaluation of patients with upper gastrointestinal bleeding, multivariate analysis demonst

195 2%]), pericardial infusion (n=1 [2%]), upper gastrointestinal bleeding (n=1 [2%]), diarrhoea (n=1 [2%

196 rs to treat patients with non-variceal upper gastrointestinal bleeding (NVUGIB).

197 The two main indications were obscure gastrointestinal bleeding (occult/anemia or overt/active

198 Clinically important upper gastrointestinal bleeding occurred in 1.3% of the PPI gr

199 amine-2 receptor blocker reduced the risk of gastrointestinal bleeding (odds ratio 0.47; 95% confiden

200 ulcer prophylaxis did not alter the risk of gastrointestinal bleeding (odds ratio 1.26; 95% confiden

201 therapeutic modality in patients with lower gastrointestinal bleeding of various aetiologies; nevert

202 Occult gastrointestinal bleeding, often arising from the lower

203 e-phase acquisition in patients with obscure gastrointestinal bleeding (OGIB).

204 st of choice in the investigation of obscure gastrointestinal bleeding (OGIB).

205 ease in aminotransferases (one), and grade 3 gastrointestinal bleeding (one).

206 Does aspirin increase gastrointestinal bleeding or hemorrhagic strokes?

207 ears, but none of the 158 patients developed gastrointestinal bleeding or hypersplenism.

208 prescribed apixaban also had a lower rate of gastrointestinal bleeding or intracranial hemorrhage (12

209 eivers were more likely to have had previous gastrointestinal bleeding or to present with cardiogenic

210 oses of acute myocardial infarction, stroke, gastrointestinal bleeding, or congestive heart failure o

211 , the critically ill, those with acute upper gastrointestinal bleeding, or for infants with low birth

212 tis, hepatic failure/cirrhosis with ascites, gastrointestinal bleeding, or postlaparotomy.

213 ardial infarction, congestive heart failure, gastrointestinal bleeding, or stroke or a diagnosis rela

214 infarction (AMI), congestive heart failure, gastrointestinal bleeding, or stroke or a diagnosis rela

215 CT) has also gained importance in diagnosing gastrointestinal bleeding, particularly in hemodynamical

216 l bleeding or recent acute bleeding (such as gastrointestinal bleeding), patients with acute ischaemi

217 Gastrointestinal bleeding, peptic ulcers, and polyps wer

218 o-therapy had 119 hospitalizations for upper gastrointestinal bleeding per 10,000 person-years of tre

219 of 359 case subjects hospitalized for upper gastrointestinal bleeding, perforation, or benign gastri

220 ing curve with regard to risks of stricture, gastrointestinal bleeding, perforation, or hospitalizati

221 .6% vs. 2.2%, p < 0.001) and higher rates of gastrointestinal bleeding, perforation, or infarction (1

222 ation (48%), followed by portal hypertensive gastrointestinal bleeding (PHGB) (32.5%), severe bacteri

223 y end points were hospitalizations for upper gastrointestinal bleeding potentially preventable by PPI

224 reinforce best-practice recommendations for gastrointestinal bleeding prevention among patients pres

225 reased hazards for device-related infection, gastrointestinal bleeding, pump thrombosis, and readmiss

226 nts and those with kidney disease had higher gastrointestinal bleeding rates with dabigatran.

227 hildren (mean age, 24 mo) who presented with gastrointestinal bleeding received endoscopic treatment

228 Age, sex, previous admission for lower gastrointestinal bleeding, rectal examination findings,

229 Gastrointestinal bleeding related to portal hypertension

230 .19-0.68; p = 0.002; I = 0%) and overt upper gastrointestinal bleeding (relative risk 0.35; 95% confi

231 nists at reducing clinically important upper gastrointestinal bleeding (relative risk 0.36; 95% confi

232 eceptor inhibitors (SSRIs) and risk of upper gastrointestinal bleeding remains controversial.

233 ild side effects occurred in seven (15%) and gastrointestinal bleeding requiring discontinuation of M

234 Gastrointestinal bleeding requiring transfusion was more

235 T trial confirmed a substantial reduction in gastrointestinal bleeding risk without apparent increase

236 A substantial reduction in gastrointestinal bleeding risk without increase in cardi

237 Significantly higher gastrointestinal bleeding risks with dabigatran 150 mg (

238 ajor bleeding (RR, 0.80 [CI, 0.63 to 1.01]), gastrointestinal bleeding (RR, 1.30 [CI, 0.97 to 1.73]),

239 Gastrointestinal bleeding scintigraphy performed with (9

240 er gastrointestinal bleeding and overt upper gastrointestinal bleeding; secondary outcomes were nosoc

241 s withdrawn from the study because of severe gastrointestinal bleeding shortly before implantation, a

242 Guidelines for nonvariceal gastrointestinal bleeding should incorporate these resul

243 e in adults, in the investigation of obscure gastrointestinal bleeding, small bowel Crohn's disease,

244 the novel oral anticoagulant (NOAC)-related gastrointestinal bleeding, summarize the management stra

245 ficantly higher risk for hospitalization for gastrointestinal bleeding than dabigatran (p = 0.0416),

246 igatran was associated with a higher risk of gastrointestinal bleeding than VKA.

247 150 mg had a significantly greater hazard of gastrointestinal bleeding than warfarin (1.23; 1.01-1.50

248 eding) and the classification used to define gastrointestinal bleeding, the Jadad quality score nor t

249 as no alarming increase in the risk of upper gastrointestinal bleeding; the effect of proton pump inh

250 with reduced risk of warfarin-related upper gastrointestinal bleeding; the greatest reduction occurr

251 tect both the source and the cause of active gastrointestinal bleeding, thereby expediting treatment

252 zed had an episode of clinically significant gastrointestinal bleeding, three patients met the criter

253 -MAMC), in Tanzania with non-traumatic upper gastrointestinal bleeding (UGIB) from July 2018 to Decem

254 ifferent prevention strategies against upper gastrointestinal bleeding (UGIB) in the general populati

255 Upper gastrointestinal bleeding (UGIB) is a common emergency d

256 Upper gastrointestinal bleeding (UGIB) is a common gastrointes

257 anagement of Patients With Nonvariceal Upper Gastrointestinal Bleeding (UGIB) refines previous import

258 Upper gastrointestinal bleeding (UGIB) remains a common medica

259 We sought to quantify upper gastrointestinal bleeding (UGIB) risk associated with lo

260 ations were positively associated with upper gastrointestinal bleeding (UGIB) secondary to peptic ulc

261 Fifty-two patients on AT with upper gastrointestinal bleeding (UGIB) were evaluated.

262 low-dose aspirin increases the risk of upper gastrointestinal bleeding (UGIB).

263 for determining risk in patients with upper gastrointestinal bleeding (UGIB); these might be improve

264 s recommended that patients with acute upper gastrointestinal bleeding undergo endoscopy within 24 ho

265 of stress ulcer prophylaxis to prevent upper gastrointestinal bleeding using H2 blockers (1A) or prot

266 Apixaban lowers the risk of major and gastrointestinal bleeding versus dabigatran and rivaroxa

267 ssociated with anemia, which may result from gastrointestinal bleeding, vitamin deficiency, or liver-

268 The rate of overt upper gastrointestinal bleeding was also reduced with omeprazo

269 Initially the source of the gastrointestinal bleeding was caused by an ulcus Dieulaf

270 Gastrointestinal bleeding was lower with dabigatran 110

271 Gastrointestinal bleeding was noted in 6 of 24 patients

272 ications from local tumor progression, fatal gastrointestinal bleeding was observed in 56% of mice th

273 alysis showed that the risk for hospitalized gastrointestinal bleeding was similar between the 2 drug

274 e-variant confounders, the incidence rate of gastrointestinal bleeding was similar during dabigatran

275 Gastrointestinal bleeding was the most frequent event.

276 A total of 5,377 patients with upper gastrointestinal bleeding were enrolled.

277 records of psychiatric inpatients with upper gastrointestinal bleeding were retrieved from the Taiwan

278 Gastrointestinal bleeding, which affected nine (<1%) of

279 Obscure gastrointestinal bleeding, which often presents as lower

280 anagement challenge of having a high risk of gastrointestinal bleeding while taking anticoagulants.

281 performance to identify patients with lower gastrointestinal bleeding who are suitable for safe outp

282 e risk score to identify patients with lower gastrointestinal bleeding who could safely avoid hospita

283 In patients with acute upper gastrointestinal bleeding who were at high risk for furt

284 1), whereas there was a greater incidence of gastrointestinal bleeding with abciximab (4.8% vs. 2.8%,

285 The risk of gastrointestinal bleeding with antiplatelet therapy is s

286 Excess risk for hemorrhagic stroke and gastrointestinal bleeding with aspirin, risk for CHD, th

287 anagement in about 50% of cases with obscure gastrointestinal bleeding with complete small bowel endo

288 r findings show no increase in risk of major gastrointestinal bleeding with direct oral anticoagulant

289 r findings show no increase in risk of major gastrointestinal bleeding with direct oral anticoagulant

290 The risk of major gastrointestinal bleeding with direct oral anticoagulant

291 We compared the risk of gastrointestinal bleeding with direct oral anticoagulant

292 hemic outcomes, despite a reduction in upper gastrointestinal bleeding with omeprazole.

293 mbers needed to treat (NNT) to prevent upper gastrointestinal bleeding with routine PPI co-prescripti

294 rovides an update on the management of upper gastrointestinal bleeding with special attention to pati

295 data are conflicting about the risk of major gastrointestinal bleeding with these drugs.

296 rospective studies that reported the risk of gastrointestinal bleeding with use of a direct oral anti

297 ascular outcomes but did show a reduction in gastrointestinal bleeding with use of a PPI.

298 ethrombosis of the portomesenteric veins and gastrointestinal bleeding, with a marginal 10-year overa

299 e primary outcome was the incidence of major gastrointestinal bleeding, with all gastrointestinal ble

300 had acute cholecystitis, and five (<1%) had gastrointestinal bleeding, with no significant differenc